Welcome to our dedicated page for Brainsway SEC filings (Ticker: BRSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Brainsway Ltd. (BRSYF) files as a foreign private issuer with the U.S. Securities and Exchange Commission, using Form 20-F for annual reporting and Form 6-K for current reports. Its 6-K filings state that they are incorporated by reference into a Form S-8 registration statement and multiple Form F-3 registration statements, showing that SEC documents are central to how the company communicates with U.S. investors.
On this page, you can review Brainsway Ltd.’s SEC filings, including Form 6-K current reports that often attach press releases as exhibits. The exhibit titles reveal key themes: neuromodulation and Deep TMS™ technologies, FDA approvals and clearances, coverage policies, and clinical trials. Examples include "BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)," "BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™," and "BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21."
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the main points of lengthy filings in plain language. Real-time updates from EDGAR allow users to see new 6-K and 20-F submissions as they appear. Investors can also access and interpret other relevant forms when available, such as registration statements and any insider-related filings like Form 4, with AI-generated highlights that clarify complex disclosures.
By combining Brainsway Ltd.’s official SEC filings with AI analysis, this page helps users understand how the company reports on neuromodulation initiatives, Deep TMS developments, and related regulatory and coverage milestones.
BrainsWay Ltd. has entered into a strategic equity financing agreement to make a minority investment in Canadian mental health provider BrainStim Health Inc.. BrainsWay will invest $1.0 million initially, with the potential for an additional $1.5 million through two milestone-based investments in a preferred, annually compounding security that includes a redemption mechanism.
This is BrainsWay’s fifth minority-stake investment in growth-oriented clinical service platforms and supports its strategy to expand access to and awareness of Deep TMS mental health treatments while the company continues focusing on scientific, clinical, and commercial advancement of its technology.
BrainsWay Ltd. filed a Form 6-K highlighting a policy change by Cigna Group’s Evernorth Behavioral Health, which serves over 18 million covered lives across 12 states. Evernorth will stop requiring prior authorization for transcranial magnetic stimulation (TMS) for contracted providers under Evernorth and Cigna Healthcare plans, effective March 6, 2026.
BrainsWay’s CEO said eliminating prior authorizations should expand timely access to TMS for patients who meet Evernorth’s criteria, including those with major depressive disorder and obsessive-compulsive disorder. The company notes its Deep TMS systems are already widely adopted in the U.S. and that it remains focused on expanding access to its three FDA-cleared indications.
BrainsWay Ltd. is changing the ratio of its American Depositary Shares (ADSs) traded on Nasdaq to match its ordinary shares on the Tel Aviv Stock Exchange. The ratio will shift from 2 ordinary shares per 1 ADS to a new 1-to-1 structure, effective before trading begins on March 3, 2026.
Each existing ADS holder will receive one additional ADS for every ADS currently held, which is economically similar to a 2-for-1 forward split of the ADSs. Because each ADS will represent half as many ordinary shares as before, the trading price of the ADSs is expected to be roughly halved after the change, without altering the underlying economic ownership.
The company’s ADSs will continue to trade on Nasdaq under the symbol BWAY, and its ordinary shares will continue to trade on the Tel Aviv Stock Exchange, with no change to the ordinary shares themselves. Management states that the goal is to simplify capital structure comparisons across exchanges and potentially enhance liquidity and accessibility for U.S. investors.
BrainsWay Ltd. filed a Form 6-K to share that Highmark Blue Cross Blue Shield, which covers over seven million lives, has issued a draft medical policy to expand coverage for its accelerated Deep TMS™ protocol for major depressive disorder in both adolescents and adults. The draft policy is anticipated to take effect in February 2026 after an open comment period and would cover BrainsWay’s SWIFT™ protocol, a short-course regimen totaling 38 treatment sessions without requiring functional MRI or other costly neuronavigation equipment.
The company notes that this follows adoption of a similar medical policy by another payer and positions accelerated Deep TMS as a more convenient option requiring fewer clinic visits. BrainsWay’s accelerated depression protocol received FDA clearance in September 2025, supported by a multisite randomized trial showing an 87.8% response rate and 78.0% remission rate, with outcomes comparable to standard Deep TMS treatment.
BrainsWay Ltd. submitted a current report for January 2026 that centers on a regulatory milestone related to depression treatment. The report attaches a press release titled “BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD).” This indicates that the U.S. Food and Drug Administration has approved Neurolief’s Proliv™Rx neuromodulation system specifically for treating major depressive disorder. The filing also notes that this report is incorporated by reference into BrainsWay’s existing Form S-8 and Form F-3 registration statements.
BrainsWay Ltd. submitted a Form 6-K as a foreign private issuer, linking it to its existing Form S-8 and Form F-3 registration statements. The filing mainly furnishes an exhibit titled “BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™”, indicating a new coverage policy related to its Accelerated Deep TMS treatment. The report was signed by the company’s Chief Executive Officer, Hadar Levy.
BrainsWay Ltd. submitted a foreign issuer report providing an update related to its Deep TMS technology. The report mainly serves to furnish an exhibit titled “BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS,” indicating the company is reporting an expansion of coverage for adolescent depression treatment using its Deep TMS system. The 6-K is also incorporated by reference into BrainsWay’s existing Form S-8 and Form F-3 registration statements.
BrainsWay Ltd. (BWAY) submitted a Form 6-K as a foreign private issuer, incorporating this report into its existing Form S-8 and Form F-3 registration statements filed in 2019, 2024, and 2025.
The report includes an exhibit titled “BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder.” This indicates that the company has begun its first clinical trial using the Deep TMS 360 system in the area of alcohol use disorder.
BrainsWay Ltd. furnished a Form 6-K reporting that it received FDA clearance for its Deep TMS therapy as an adjunct treatment for major depressive disorder (MDD) in adolescents aged 15 to 21. The update is provided as an exhibit to the report. The company also notes that this Form 6-K is incorporated by reference into its existing U.S. registration statements on Form S-8 and Form F-3.
BrainsWay Ltd. (BWAY) furnished a Form 6-K for November 2025, providing an Investor Deck as Exhibit 99.1. The report notes that the submission is a foreign private issuer filing under the Securities Exchange Act.
The company states that this Form 6-K is incorporated by reference into its existing registration statements: a Form S-8 filed April 22, 2019 and Forms F-3 filed July 22, 2024 and April 22, 2025. The filing itself contains no financial results or transaction details beyond the inclusion of the investor presentation.